Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy

PURPOSE: B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy results in high remission rates in patients with relapsed/refractory (R/R) multiple myeloma. However, the factors associated with prognosis following CAR T-cell therapy are unknown. PATIENTS AND METHODS: Between...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mingming, Zhou, Linghui, Zhao, Houli, Zhang, Yanlei, Wei, Guoqing, Hong, Ruimin, Wu, Wenjun, Xu, Huijun, Wang, Linqin, Ni, Fang, Cui, Jiazhen, Peng, Shuixiu, Huang, Chih-Hua, Chang, Alex H., Hu, Yongxian, Huang, He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401500/
https://www.ncbi.nlm.nih.gov/pubmed/34548316
http://dx.doi.org/10.1158/1078-0432.CCR-21-2031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401500/
https://www.ncbi.nlm.nih.gov/pubmed/34548316
http://dx.doi.org/10.1158/1078-0432.CCR-21-2031

Ejemplares similares